Critically ill patients frequently experience acute brain dysfunction in the form of coma or delirium, both of which are common during acute and chronic critical illness (CCI). These manifestations of brain dysfunction are associated with numerous adverse outcomes during acute critical illness, including prolonged hospitalization, increased healthcare costs, and increased mortality. The prognosis of CCI patients with coma or delirium has not yet been thoroughly studied, but preliminary studies suggest this population is at high risk for detrimental outcomes associated with acute brain dysfunction. Additionally, a high percentage of patients who survive acute or CCI suffer from long-term brain dysfunction, which manifests primarily as memory deficits and executive dysfunction and is predicted by brain dysfunction in the ICU. Interventions directed at reducing the burden of brain dysfunction during critical illness have shown promise in studies of patients with acute critical illness, but these therapies have yet to be studied during CCI. Thus, multicenter randomized trials are needed to determine which interventions are most effective for such patients. Until these data are available, management strategies that have been proven beneficial during acute critical illness-such as reduction of sedative exposure, especially to benzodiazepines, and early use of physical and occupational therapy-should be employed during the treatment of patients with CCI.
Introduction
Brain dysfunction is one of the most common forms of organ failure complicating critical illness. Acutely, brain dysfunction during critical illness most often manifests as coma or delirium, with coma being a state of unarousable unresponsiveness, 1 and delirium being an acute and fluctuating disturbance of both consciousness and cognition. 2 Both forms of brain dysfunction can result from a variety of neurologic insults, including ischemic or traumatic brain injury, toxic or metabolic derangements, or as side effects of medications, especially some sedative agents frequently used in the ICU.
Not only is brain dysfunction common during the active phases of critical illness, but this often insidious complication of critical illness may persist for months to years in the form of ongoing cognitive impairment that prevents survivors from returning to their pre-critical illness level of functioning. Though a large and growing number of studies have demonstrated that long-term brain dysfunction is common among survivors of critical illness, the mechanisms and specific risk factors remain unproven and may be multifactorial in this population of patients who are exposed to many factors theorized to contribute to poor cognitive outcomes.
During the past decade, the vast majority of investigations that have examined brain dysfunction during and after critical illness have limited their focus to patients with acute critical illness, but it is likely patients with chronic critical illness (CCI) who suffer the largest burden of brain dysfunction due to critical illness. This review will examine the existing knowledge regarding acute and long-term brain dysfunction among patients with CCI, reviewing what is known about the prevalence of both acute and long-term brain dysfunction in this vulnerable population, describing the outcomes associated with brain dysfunction in this setting, and highlighting approaches to management that may improve the cognitive outcomes of patients with CCI.
Coma and Delirium During Critical Illness
Though the frequency of coma during critical illness may be changing over time as sedation practices and other treatments evolve, studies from the last decade suggest that coma is common during critical illness. One study, for example, found that coma was observed on one third of all ICU days among 275 mechanically ventilated medical ICU patients. 3 A more recent study reported that more than half of 335 mechanically ventilated medical ICU patients had coma 1-2 days after intubation, and the median duration of coma in this cohort was 2-3 days. 4 Whether due to illness or sedatives, a minority of ICU patients (eg, 18% in one study of mechanically ventilated patients) have coma that persists throughout their ICU stay, which for these patients nearly always culminates in death. 5 In contrast with patients in a persistent vegetative state without other organ dysfunctions, patients with CCI who remain comatose have a very high case-fatality rate. In some cases, such patients may be identified within a few days of ICU admission; the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment (SUPPORT) investigators, 6 for example, found that on day 3 of their study, comatose patients with 4 of 5 risk factors-abnormal brain stem response, absent verbal response, absent withdrawal response to pain, creatinine Ն 1.5 mg/dL, and age Ͼ 70 years-had a 97% 2-month mortality. The majority of comatose ICU patients, fortunately, awake from coma, but many continue to have acute brain dysfunction in the form of delirium.
Delirium occurs in 60 -80% of critically ill patients with acute respiratory failure requiring mechanical ventilation, 4,7-10 whereas 40 -50% of critically ill patients who are not mechanically ventilated will develop delirium during their ICU stay. 11, 12 The higher prevalence of delirium observed among mechanically ventilated ICU patients may be attributable to a high severity of illness and exposure to numerous delirium risk factors, especially psychoactive medications. These factors may contribute to the fact that delirium in the ICU often persists for days; studies of mechanically ventilated ICU patients have observed a median duration of delirium of 2-3 days, with up to one quarter of patients being delirious for 5 or more days. 13, 14 In contrast to the large number of studies that have evaluated patients with acute critical illness for brain dysfunction, only a small number have examined patients for brain dysfunction during CCI (Table 1) . Most of these studies focused on the period of time shortly after transfer to a facility specializing in the care of patients with CCI (eg, a dedicated step-down unit or a long-term acute care hospital). Within 1-3 days of transfer, between 17% and 70% of patients in these studies had brain dysfunction: 1-50% were comatose, 2-15% were delirious, and one study reported that 14% had subsyndromal delirium, an intermediate state of brain dysfunction considered less severe than delirium. 20 Two studies 16, 18 followed patients prospectively during the course of their illnesses and found 16, 18 ; the weekly prevalence of acute brain dysfunction in one of these studies is shown in Figure 1 . All of the studies examining brain dysfunction in patients with CCI were single-center investigations; differences in severity of illness, use of sedatives, and timing of transfers all may have contributed to the varying rates of brain dysfunction observed. Though large, prospective, multicenter studies are needed to better gauge the general prevalence of coma and delirium during CCI, existing studies clearly demonstrate that brain dysfunction remains a common organ failure after the transition from acute to CCI.
Delirium was considered for decades to be an inconsequential (albeit bothersome) complication of being treated in an ICU, where environmental factors (such as loud noise and lack of sunlight) were believed to cause "ICU psychosis," which resolved prior to ICU discharge and had no lasting effects. Evidence to the contrary has now made it clear that delirium is independently associated with numerous adverse outcomes, including self-extubation and removal of devices, 21 prolonged ICU 22 and hospital stays, 11, 23 and increased mortality. 5, 14, 22 In a study of 275 mechanically ventilated patients, Ely et al 5 found that patients who developed delirium at any time during their ICU stay had significantly higher 6-month mortality than those without delirium, after adjusting for potential confounders such as age, coma, and severity of illness. In addition, duration of delirium was an independent predictor of 6-month mortality, with each additional day of delirium increasing the hazard of dying by 10%. These results have since been duplicated by numerous studies, including 2 that specifically found duration of delirium in the ICU to independently predict 30-day 22 and 1-year mortality. 14 Patients who survive critical illness despite long periods of delirium are at high risk for another adverse neurologic outcome, long-term cognitive impairment. The acute symptoms of delirium, including disturbances in consciousness, resolve for most long-term survivors, but other symptoms of brain dysfunction can persist for months to years. In the only study to date to examine the relationship between duration of delirium in the ICU and long-term cognitive function, longer periods of delirium were associated with worse scores on a battery of 9 cognitive tests 1 year after the episode of delirium, even after adjusting for potential confounders such as age, severity of illness, and preexisting cognitive impairment (Fig. 2) . 13 Despite a large and growing body of evidence showing that coma and delirium have great prognostic importance during the acute period of critical illness, the prognostic importance of acute brain dysfunction in patients with CCI is less clear. Though Nelson et al 16 found that more days of delirium during CCI were significantly associated with discharge to a post-acute care facility as well as prolonged hospital stays and poor long-term functional status, the same study found no significant association between delirium and short-or long-term mortality. Similarly, Ceriana et al 18 found no correlation between scores on the Intensive Care Delirium Screening Checklist 24 and mortality among step-down unit patients, the majority of whom had CCI. Finally, Jubran and co-workers 19 found that transient acute brain dysfunction was actually associated with improved survival in a multivariable analysis of long-term acute care patients. Nearly one third of patients in this study had transient coma and/or delirium, whereas another third had normal mental status, and the final third had persistent coma-delirium; thus, the results regarding transient coma-delirium and survival may primarily reflect the comparison with those patients whose acute brain dysfunction was persistent, a group whose outcomes one would expect to be worse than those with transient delirium.
With only limited data available on the short-term out- comes associated with delirium during CCI and no data available on long-term outcomes, firm conclusions cannot yet be made regarding the prognostic importance of delirium in this patient population. But, with preliminary data suggesting that delirium often persists for more than a few days during CCI, 16 and numerous ICU studies showing that duration of delirium predicts adverse long-term outcomes, 5, 13, 14, 22 it is reasonable to hypothesize that chronically critically ill patients with prolonged delirium are at high risk for poor long-term outcomes, especially longterm brain dysfunction; this hypothesis can and should be tested in future studies.
Long-Term Brain Dysfunction in Survivors of Critical Illness
Survivors of acute critical illness usually experience resolution of coma and delirium as their acute illness improves. Despite this evidence of some neurologic improvement, brain dysfunction often persists, taking on a different form. Over a dozen studies have demonstrated that longterm cognitive impairment affects between 20% and 80% of ICU survivors, depending on the population studied and the methods used to identify impairment. Hopkins et al, 25 for example, examined 55 patients 1 year after mechanical ventilation for ARDS and found that 78% were impaired in one or more cognitive domains such as memory, concentration, attention, and processing speed. The majority of studies, in fact, have found that memory is impaired in many patients for months to years after a critical illness; the other domain of cognition most commonly impaired is executive function. 26 The cognitive deficits identified in these studies adversely affect patients in numerous ways, making it difficult or impossible to return to work, and reducing quality of life. Rothenhausler and colleagues 27 examined 46 ARDS survivors an average of 6 years after their illness and found that the 11 (24%) with cognitive impairment were unable to return to work and had poor health-related quality of life, which was independently associated with long-term cognitive impairment.
The rigorous methods used to assess cognitive function in studies of patients who survived acute critical illnesswhich included prospective examination of patients with comprehensive neuropsychological batteries-have not yet been applied to study survivors of CCI, but 4 investigations have identified long-term brain dysfunction in this population using other methods (Table 2 ). In these studies, which examined patients 3 months to 2ϩ years after CCI, 40 -77% of patients exhibited signs of long-term brain dysfunction, manifest as poor Mini-Mental State Examination scores or inability to respond to a telephone interview. The specific nature and severity of the long-term cognitive deficits that affect survivors of CCI are not known, but it is likely that the domains of cognition that are impaired in this population are similar to those observed in investigations of survivors of acute critical illness. The preliminary data from studies of CCI survivors suggest that long-term cognitive impairment in this population is often severe; a Mini-Mental State Examination score Ͻ 15, the cutoff used in one study, represents a cognitive state similar to that observed in patients with moderate dementia. Detailed studies are needed to fully elucidate the prevalence and character of long-term cognitive impairment among survivors of CCI.
Despite the high prevalence and adverse effects of longterm cognitive impairment in survivors of both acute and chronic critical illness, this complication is often overlooked by clinicians and misunderstood by patients and their caregivers. In a study of ARDS patients, Hopkins and co-workers 31 found that 46 (70%) of 66 survivors were cognitively impaired at hospital discharge, yet only 9 patients (Ͻ 20% of those who were impaired) were subsequently identified as having cognitive impairment by clinicians caring for these patients. Not only are these deficits often unaddressed by clinicians during the long period of recovery from critical illness, but the potential for poor cognitive outcomes is frequently not discussed with critically ill patients or their families. Nelson et al 32 studied patients with CCI to determine the informational needs of patients and their families. Among 96 surrogates asked if they received information about "what the patient's cognitive status (ability to think and understand, mental state) is expected to be when he leaves the hospital," only 33 (34%) reported receiving any information. In contrast, 99% of respondents rated information about long-term cognitive outcomes as important to decision making, a result in keeping with the findings of an earlier study by Fried and colleagues. 33 They surveyed 226 seriously ill patients to determine outcomes considered important when determining treatment preferences; cognitive impairment was reported by these patients to be a less acceptable outcome than death. Thus, though it remains unclear how best to identify patients at highest risk for long-term cognitive impairment after CCI, the very real possibility of such an outcome should be acknowledged by clinicians and discussed openly with patients and their surrogates.
Management of Brain Dysfunction During Critical Illness
The management of brain dysfunction during and after CCI has not been specifically examined, but a growing body of literature on brain dysfunction during the period of acute critical illness points to a number of treatment strategies that may be of import for the population with CCI. As with any patient, an acute change in mental status (whether new-onset delirium or coma) during CCI should prompt an evaluation for an etiology and/or modifiable risk factors. Signs of stroke or seizure accompanying newonset coma, for example, should prompt directed evaluations with neuroimaging or electroencephalography, whereas newly delirious patients should be evaluated for one or more of the numerous modifiable risk factors for delirium identified in ICU studies, including infection/sepsis, hypotension, hypoxemia, hyponatremia, hypocalcemia, azotemia, and exposure to sedating medications. 34 -36 The identification of such a risk factor in the setting of newonset delirium may afford the clinician an opportunity to intervene, since treating the risk factor may interrupt the process of brain dysfunction.
Though placement of tracheostomy-a nearly universal treatment for patients with CCI-may lead to less sedative use, 37 exposure to sedating medications remains common during CCI and represents a potential risk factor for brain dysfunction in this vulnerable population. Nelson et al 16 reported that 128 (63%) of 203 respiratory care unit patients received benzodiazepines during CCI, and 160 (79%) received opioid analgesics. Though analyses of sedative doses and acute brain dysfunction in this study found no associations, benzodiazepine exposure has consistently been associated with delirium in ICU studies. Pandharipande and colleagues, 36 for example, found that lorazepam dose independently predicted the probability of delirium in a study of mechanically ventilated medical ICU patients; those treated with higher doses of lorazepam on a given ICU day were more likely to be delirious the following day than patients who received small doses (Ͻ 3 mg) or no lorazepam. The median benzodiazepine dose used in the respiratory care unit studied by Nelson et al 16 was 1 mg/d in lorazepam equivalents, which may explain the lack of an association with delirium in that study. Those patients with CCI who receive higher doses of benzodiazepines are likely at increased risk for delirium, as this association has been observed in medical, 36,39 surgical, 40 mixed, 21 trauma, 40 and burn 41 ICU patients who are moderately or heavily sedated with benzodiazepines. Thus, benzodiazepines should be avoided, whenever possible, during the treatment of patients with CCI.
When sedation is needed to manage patients with CCI, alternatives to benzodiazepines include opioids, which can provide analgesia and sedation, as well as propofol, dexmedetomidine, and antipsychotic medications. None of these agents have been studied specifically in the setting of CCI, so results from studies during acute critical illness should be extrapolated with some caution. Signs of agitation, anxiety, or discomfort during CCI should always prompt clinicians to consider whether opioids are needed, since pain is common during CCI; two thirds of patients reported pain in one study of CCI, with nearly half of all patients reporting moderate to severe pain. 42 The use of opioids in this setting will not only control pain but may also reduce the risk of delirium. 43 With its rapid onset of action, propofol is an attractive option for the treatment of acute agitation in patients who have protected airways, especially for severe agitation that requires immediate resolution. Compared head-to-head with benzodiazepines in several randomized trials, propofol provided more accurate sedation (ie, less oversedation) and led to shorter ventilator time. 44 -46 Time-limited courses of propofol sedation, in contrast to longer-term continuous sedation, have been used effectively in the ICU and should be considered when managing severe agitation during CCI. Strøm et al 47 included 6-hour courses of propofol in a protocol that emphasized "no sedation," prioritizing asneeded morphine and haloperidol over continuous sedation in the management of mechanically ventilated ICU patients; the no sedation protocol reduced time on the ventilator, in the ICU, and in the hospital, compared with standard of care. Similar protocols should be developed to specifically address the needs of patients with CCI, many of whom develop agitation 48 or other symptoms prompting treatment with sedatives; until such protocols have been tested in this unique patient population, protocols that have been rigorously studied and found to be beneficial among patients with acute critical illness should be considered for the management of patients with CCI. 4, 49, 50 Dexmedetomidine, another alternative to benzodiazepine sedatives, has been studied recently during acute critical illness and may offer advantages in the management of patients with CCI. Whereas propofol, similar to the benzodiazepines, potentiates ␥-aminobutyric acid type A (GABA A ) receptor activity to produce sedation, dexmedetomidine sedates via stimulation of central ␣ 2 -adrenergic receptors. This GABA-sparing mechanism of action may explain the results of 2 randomized, double-blind, multi-center trials that found that mechanically ventilated ICU patients who were sedated with dexmedetomidine had less delirium on a daily basis than those sedated with a benzodiazepine. 10, 38 Dexmedetomidine was also compared with haloperidol for the treatment of agitated delirium during acute critical illness; in a small randomized trial, 51 those treated with dexmedetomidine were extubated and discharged from the ICU more quickly than patients treated with haloperidol, suggesting dexmedetomidine may be effective both for sedation and possibly for treatment of agitated delirium, though dexmedetomidine for this indication needs to be studied in larger clinical trials.
Haloperidol remains the most widely used medication for the treatment of delirium during critical illness, with atypical antipsychotics growing in popularity. Nearly 40% of respondents in a recent international survey, for example, reported using atypical antipsychotics to manage delirium, whereas almost 90% reported using haloperidol for this indication. 52 Similarly, Nelson et al 16 found that two thirds of patients with CCI received antipsychotics during their respiratory care unit stay. The use of this class of medications for the treatment of delirium during both acute and chronic critical illness is supported primarily by results of studies conducted outside the ICU. Hu et al 53 studied haloperidol and olanzapine in a randomized, placebo-controlled trial of older patients with delirium and found that both the typical and the atypical antipsychotic resulted in more rapid resolution of delirium than did placebo. Similarly, Kalisvaart and co-workers 54 found that haloperidol treatment prior to hip surgery led to a shorter period of postoperative delirium, compared with placebo. Only 2 placebo-controlled trials, both pilot in nature, have examined the effects of antipsychotics among patients with acute critical illness. In one study, our research team found no difference in duration of acute brain dysfunction among mechanically ventilated ICU patients treated with haloperidol versus ziprasidone versus placebo. 55 Alternatively, in a study of delirious ICU patients who uniformly failed to respond to haloperidol, Devlin et al 56 found that addition of quetiapine rather than placebo resulted in earlier resolution of delirium (Fig. 3) . With the only 2 placebocontrolled trials of antipsychotics for delirium in the ICU being very small and giving conflicting results, it is impossible to know at this time whether these medications are efficacious for delirium during critical illness. We are therefore coordinating a large, multicenter, phase 3, randomized controlled trial 57 to answer this question, but future research will be needed specifically to examine the effect of antipsychotics during CCI. Until such data are available, it is likely that antipsychotics will continue to be recommended for the treatment of delirium during critical illness, whether acute or chronic. 58 The management of brain dysfunction during critical illness is not limited to pharmacologic interventions.
Though not yet studied in an ICU population, several multicomponent, nonpharmacologic strategies have been found to reduce delirium incidence among acutely ill older patients. 59 Similar approaches are likely to be of benefit for patients with CCI, and interventions such as orientation, nonpharmacologic sleep protocols, and vision/hearing aids are generally safe and require little in the way of resources. A nonpharmacologic intervention that can, in contrast, be very resource intense-early physical and occupational therapy (often referred to as early mobility)-has recently been examined in several different ICU populations. In a study of 103 respiratory ICU patients, a population that included many CCI patients, Bailey and colleagues 60 showed that early mobility was safe and feasible. Over two thirds of the patients, in fact, were able to ambulate Ͼ 100 feet at the time of ICU discharge. Subsequently, multiple interventional studies, both randomized 61 and non-randomized, 62, 63 have examined early physical/occupational/mobility therapy during acute critical illness and found these interventions to improve numerous outcomes, such as return to functional independence and hospital stay. Two of these trials specifically assessed patients for delirium and found that early physical/occupational therapy reduced the duration of delirium during critical illness, 61, 63 suggesting that early physical activity-an important component of delirium prevention programs previously studied outside the ICU-might significantly reduce brain dysfunction during acute and chronic critical illness.
A complementary approach to the management of brain dysfunction in the midst of critical illness is the rehabilitation of cognitive function after critical illness. Though a large body of literature supports the use of cognitive rehabilitation in other patient populations, such as those with traumatic brain injury, this intervention has only recently been studied among survivors of critical illness. In a small, Fig. 3 . Effect of treatment with quetiapine versus placebo on resolution of delirium in 36 patients with acute critical illness. Both groups of patients were treated using the same as-needed intravenous haloperidol protocol. Compared with placebo, the addition of quetiapine resulted in faster resolution of delirium (P ϭ .001).
(From Reference 56, with permission.) pilot investigation, Jackson and co-workers 64 randomized patients being discharged from the hospital after acute critical illness to usual care or a multicomponent rehabilitation program combining cognitive, physical, and functional training. Three months later, those managed with the rehabilitation program had better cognitive and functional outcomes than those in the control group, a finding that should prompt further investigation in large, multicenter trails of cognitive rehabilitation after critical illness.
Future Directions
A substantial body of literature has grown over the past decade to inform critical care practitioners about the prevalence, outcomes, and management of acute and long-term brain dysfunction attributable to critical illness. The large majority of these investigations, however, have been limited to patients with acute critical illness. Therefore, targeted studies are needed to elucidate the effects of CCI on the brain and to identify therapies directed at brain dysfunction during CCI that are safe and efficacious. Specifically, multicenter studies with a broad array of chronically critically ill patients are needed to examine the prevalence and outcomes of coma and delirium in this population as well as long-term brain dysfunction in survivors of CCI. Risk factors for and pathophysiologic mechanisms of acute and long-term brain dysfunction due to CCI should also be thoroughly illuminated. The latter, mechanisms of brain dysfunction, have only recently been studied during acute critical illness and only in small, hypothesis-generating studies. Being preliminary in nature, the findings of these studies are not reviewed here, but these results and those of recent animal studies should guide investigations of the mechanisms of brain dysfunction during CCI. Lastly, though interventions that effectively reduce brain dysfunction during acute critical illness should be implemented among those with CCI until more data are forthcoming, randomized trials are needed to determine whether interventions used during acute critical illness are effective in CCI. In addition, novel interventions that may be of particular benefit to patients with CCI should be sought and studied in this setting.
Summary
Acute brain dysfunction, in the form of coma and delirium, occurs frequently during both acute and chronic critical illness, and patients who survive either form of critical illness remain at high risk for ongoing long-term brain dysfunction. A growing number of studies have found that coma, delirium, and long-term brain dysfunction are associated with numerous adverse outcomes among acute critical illness patients, including prolonged hospitalizations, increased healthcare costs, and increased mortality.
Though not yet well studied in the setting of CCI, brain dysfunction may be associated with adverse outcomes for these vulnerable patients. Thus, interventions to prevent and/or treat acute and long-term brain dysfunction should be implemented in the care of patients with CCI. Multicenter randomized trials are needed to determine which interventions are most effective for such patients, and until these data are available, management strategies that have been proven beneficial during acute critical illness-such as reduction of sedative exposure, especially to benzodiazepines, and early physical and occupational therapy-should be employed during the treatment of patients with CCI. 
Discussion
White: What proportion of decreased cognitive function can you actually attribute to the ICU experience? Without before and after data, you don't know what their cognitive function was before they entered the study, because you can't get that. Are there data on patients of similar age and function where they could figure out what percent of the decrement in cognitive function was attributable to the CCI and how much of it was that's just the way they were?
Girard:
The inability to directly assess pre-ICU cognitive function has, in many ways, been the Achilles heel in this area of research. You can't, in most cases, identify patients and test them prior to critical illness, because an ICU stay is not like a surgery that is planned. Instead, it usually happens unexpectedly. But in the last couple of years there have fortunately been some very elegant studies that have addressed this challenge by making use of long, prospective cohort studies involving older patients who were being assessed at regular intervals for cognitive impairment. When some of these patients developed critical illness, the opportunity arose to compare preand post-ICU cognitive function. In one of these studies, Jack Iwashyna and his colleagues 1 used the Health and Retirement Study cohort and found that patients who had been tested before and after episodes of severe sepsis requiring ICU admission had significantly higher rates of new cognitive impairment. Unlike most studies of ICU survivors, these were patients who were tested before and after severe sepsis, and the risk of developing new cognitive impairment after critical illness was significantly increased, compared with patients who did not develop severe sepsis.
Bill Ehlenbach and his colleagues 2 analyzed patients in a similar cohort study conducted in Seattle. They studied the effect of acute hospitalizations and ICU stays among patients who had been tested prior to and after those events. They found a very similar result. The rate of cognitive impairment went up significantly for those patients who had a hospitalization or an ICU stay, compared with those who did not. 
MacIntyre:
The reason I brought it up is because it is something we can modify. This practice of doing daily chest x-rays at 3:00 AM and daily blood draws at 4:00 AM and daily vital signs at 5:00 AM: maybe we could rearrange our schedule to better fit theirs.
Girard: I agree completely. We've alluded multiple times today to reducing sedation. Our studies with EEG found that patients who were receiving very high doses of benzodiazepines, which are now infrequently used in our ICU, had very little slow-wave sleep. On physical exam, these patients were comatose, so the ICU team often said the patients were "resting" or "asleep," but they are not sleeping. When you look at the EEGs, the benzodiazepines appeared to be leading to the least amount of slow-wave of any of the patients we studied.
Fan: There may be data forthcoming. Johns Hopkins has launched a sleep quality improvement project, and they are using a staged intervention to improve environmental and pharmacologic alterations to sleep in ICU patients. They're collecting sleep questionnaires and monitoring delirium and doing some simple neurocognitive testing. So there may be some more information coming on sleep quality and ICU delirium. Tim, did that study by Jim Jackson 1 specifically look at physical rehabilitation? Do you have comments on the role of neurocognitive rehabilitation in the ICU, like getting patients in the ICU to play Scrabble or Sudoku?
Girard: That study examined a combined cognitive and physical rehabilitation program that was started after hospital discharge. The intervention group received in-home physical therapy via either a physical therapist who went to the patient's home or a telecommunications system that was brought to the patient's home and set up so that the physical therapist could remotely direct the therapy. They also received a specific type of cognitive rehabilitation, goal management training, that's shown significant benefit in other patient populations.
Regarding other potential interventions, such as having them do cognitively stimulating activities, we're currently doing a pilot study called ACT-ICU (Activity and Cognitive Therapy in the ICU) to determine whether an intervention that combines cognitive and physical therapy very early during critical illness is feasible and safe. As soon as the patient passes some basic safety criteria, very early in the course of their illness, we're doing physical and cognitive therapy that involves many components, including games and other stimulating activities.
Muldoon:* You showed a slide that said about 50% of delirium is missed, and another slide that showed that, for those known to be delirious, antipsychotics are no better than placebo. That begs the question, what's the harm in missing the diagnosis, in the absence of a treatment that works?
Girard: That is a very important question. At this point it's a question that I can only answer philosophically. There hasn't been a study that shows that if you identify delirium and then treat it that you will change long-term outcomes. But we also don't know that you can't change long-term outcomes. So I would say that, by assessing for and recognizing delirium, you may change your approach to that patient's management in ways that will benefit them.
For example, evaluating for and diagnosing delirium may make you more likely to use only light sedation, or even no sedation or medications that are less likely to contribute to delirium. Will it change their long-term cognitive outcomes? We don't know yet, because it hasn't been studied. Right now the only definitive risk factor we've identified for long-term * Sean R Muldoon MD MPH, Kindred Healthcare, Hospital Division, Louisville, Kentucky. cognitive impairment after critical illness is duration of delirium in the ICU. Until we know any different, it seems appropriate to me-if not for any other reason, then at least for purely prognostic purposes-to assess for delirium.
If we're going to talk with families about the potential for long-term cognitive impairment in their critically ill loved ones, then what are we going to say about risk factors? The only thing that I know to say is that they've been delirious for a long time or they haven't been delirious for a long time. If a family member says to me, "I saw in the Wall Street Journal that patients end up with cognitive impairment months or years after being in the ICU. Is that going to happen to my husband?" then there's at least something that I can look to as a prognostic factor. How good am I at predicting that? I'm not that good, and I'd tell them that, but it's something I can talk with them about, prognostically.
Carson: From my own experience in delirium studies, the biggest help of the delirium screen is that it makes up for the fact that we can't recognize hypoactive delirium just by looking at a patient. The patient may have been agitated, received a drug, and now they look just fine. Their eyes are open and they're looking at you and even tracking you a little bit, so from the door or even the bedside they look fine. But if you do the delirium assessment, they're not there. A 2-minute assessment once a day by the nurse is enough to let you know that, whatever is going on with this patient medically, there is delirium present. And is there something we can do differently to make it not present? We may not be able to give a drug to make it go away, but we could certainly withhold drugs that may be contributing, or change the environment, or what have you.
Girard:
That goes back to the comment about parachutes. 1 There are certainly some circumstances where assessing for delirium has benefits that are obvious but may never be tested or proven. Take, for example, a patient who is not delirious and then becomes delirious during their ICU stay; new-onset delirium can be a warning sign that prompts diagnostic assessments, which can benefit the patient.
Among older patients with sepsis, altered mental status or delirium is a very common presenting sign, and fever is less common than among younger patients. So if you're evaluating patients in or outside the ICU and they newly develop deliriumsomething you're often only going to detect if you're using a structured assessment tool-that tells you to look for a reason. Do they have an infection you haven't diagnosed yet? Do they have new renal failure or electrolyte abnormalities?
These potential changes in management are things that we're never going to study in a randomized controlled trial. Patients who have a urinary tract infection detected because they were noted to be delirious will not be randomized to treatment versus no treatment. That's the parachute idea: we don't need a randomized controlled trial to know that it's beneficial.
